Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) decreased during the last reporting period, falling from 174.14M to 173.93M. This put 35.4% of the company's publicly available shares ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果